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Misonidazole reduces blood flow in two experimental murine tumours
J.C. Murray & V.S. Randhawa
Cancer Research Campaign, Gray Laboratory, P.O. Box 100, Mount Vernon Hospital, Northwood Middlesex
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Summary The effects of single doses of misonidazole (MISO) on blood flow and vascular volume in the
SaFA and CaNT tumours and normal tissues of the mouse have been studied. MISO was administered in the
dose range 250-1,000mgkg- and blood flow measured at different times after MISO by the 86RbCl
extraction technique. Vascular volume was assessed by the distribution of 51Cr-labelled red blood cells. MISO
at doses of 500 mgkg- or greater decreased flow in both tumours by up to 60% within 2h. Flow remained
reduced for up to 24h. Similar but less profound changes were seen in the skin, although flow had recovered
by 24h. Only slight changes were seen in muscle, and none in kidney. The apparent loss of flow in tumours
seen after large single doses of MISO may have important implications for its use as a chemosensitizer.
Misonidazole (MISO), a hypoxic cell radiosensitizer in vivo
and in vitro (Adams et al., 1976; Fowler et al., 1976) can also
act as a chemosensitizer, potentiating the effects of various
chemotherapeutic agents (McNally, 1982; Millar, 1982;
Siemann, 1984). In a recent study of the effects of MISO
combined with melphalan on the vasculature of a murine
sarcoma (Murray et al., 1987) we presented evidence that
this combination of drugs profoundly affected vascular struc-
ture and function at doses which in combination produced
significant growth delay. Our results, obtained using a
fluorescent dye (Hoechst 33342) perfusion technique, indi-
cated that MISO alone might be largely responsible for these
vascular effects. We have therefore examined the effects of
MISO on vascular function in the same tumour model using
alternative techniques to measure both vascular volume and
blood flow. The aim of these studies was to (a) corroborate
our earlier observations, (b) determine the time course and
dose-dependence of these effects, and (c) extend these studies
to another tumour. In addition we have compared the effect
on the sarcoma with that on several normal tissues, in an
attempt to determine whether the observed effects were the
result of a direct action on the tumour vasculature, or of a
more general physiological effect.
Materials and methods
Tumours
The SaFA sarcoma was transplanted by trocar as 1 mm3
pieces subcutaneously onto the backs of WHT/Gy f BSVS
mice. The anaplastic carcinoma CaNT was transplanted s.c.
on to CBA/Ht Gy f TO mice by injection of a cell
suspension in saline, obtained by mechanical disruption of a
tumour.
Drug treatment
Misonidazole (MISO, Roche Ltd), was administered by i.p.
injection of a solution of the drug dissolved in sterile saline
at a series of concentrations representing total doses ranging
from 250-1,000omgkg- 1
Vascular perfusion estimated by Hoechst33342
Vascular perfusion of the SaFA tumour was assessed at
different times (2, 12 and 24h) after MISO treatment. One
minute before sacrifice, tumour-bearing mice were injected
intravenously with the fluorescent DNA-binding dye
Hoechst 33342, dissolved in saline to a concentration of
4mgml -1, and administered at a dosage of 40 mgkg-1
(Murray et al., 1987). Tumours were excised and frozen for
serial sectioning. Frozen 6,m sections were examined with a
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Nikon microscope equipped with epifluorescence, and the
percentage perfused volume was estimated by Chalkley point
counting of the Hoechst-outlined vessels (Smith et al., 1987;
Murray et al., 1987). Only the SaFA tumour was assessed in
this way as Hoechst 33342 diffuses rapidly throughout
normal tissues, presumably due to the abundance of normal
vasculature, making point counting almost impossible.
Relative bloodflow estimated by 86RbCt extraction
Relative blood flow was estimated in tumours and normal
tissues by the 86RbCl extraction technique (Sapirstein, 1958).
At 1 min prior to sacrifice, mice were injected with 50pl of a
saline solution of 86RbCl (Amersham Intrnational PLC)
containing a total activity of 185 KBq. Mice were sacrificed
as described above and tissues collected, weighed and
counted for radioactivity. Relative blood flow is expressed as
percent of cardiac output per gram of tissue. Total dpm in
the dissected tissue is divided by the total dpm injected, after
subtracting the amount of radioactivity remaining in the tail,
which is assumed not to have entered the circulation.
As the emission characteristics of 51Cr and 86Rb differ
sufficiently to be distinguished by a suitable scintillation
counter, it was possible to estimate radioactivity from both
isotopes in the same tissue sample. Thus blood volume
(5'Cr) and relative blood flow (86Rb) could be determined
for the same tumour or normal tissue sample by sequential
injection of the two isotopes at 30min (51Cr) and 1 min
(86Rb) prior to sacrifice.
Vascular volume estimated by 51Cr-labelled red blood cells
Vascular volume of tumours and normal tissues was also
measured by estimating the proportion of red blood cells,
previously labelled with 51Cr, in various tissues 30min after
intravenous injection (Song & Levitt, 1970). To prepare
labelled red blood cells, 10ml of blood was collected from
WHT mice into heparinized tubes and spun for 10min at
1,500 rpm. The supernatant was discarded and the volume
restored with saline. 51Cr (33.3 MBq) in the form of a
solution of sodium chromate (Amersham International PLC)
were added and the mixture shaken gently at room tempera-
ture for 30 min. The labelled blood was centrifuged and
washed several times with saline. Finally the volume of the
red blood cells was restored to 10ml. Mice were injected
with 0.1 ml of the labelled red blood cells via the tail vein
30 min prior to sacrifice. Animals were anaesthetized with
Penthrane and blood collected via the jugular vein. Tissues
were excised, weighed, and counted with a gamma-counter
(LKB Wallac). Vascular volume was estimated by determin-
ing the ratio of the specific activity of 51Cr in dpmmg-'
tissue compared to that in circulating blood at the time of
sacrifice, and expressing this as a percentage. This method
assumes even distribution of red blood cells within the
plasma. This is almost certainly not the case in some
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capillaries, where the relative number of red blood cells is ^A a
low per unit volume of plasma, and therefore the method
will tend to underestimate the contribution of the capillary
fraction to total vascular volume.
0
Statistics O
Significance levels were determined by Student's t-test. In o
general data represent pooled values from three separate C
experiments, four to six determinations being made for each
time or dose point.
G)
E Results
Vascular parameters of tumours and normal tissues
of control mice .
Table I shows estimates of relative blood flow for tissues I
obtained from control mice of both strains using the 86Rb
extraction technique. Kidney demonstrated the highest flow
(26.3%g-1), followed by muscle (2.8%g-1). Flow in the
SaFA tumour (1.8%g-1) lay between that for muscle and
skin. Flow in the CaNT was slightly lower than the SaFA, at
1.l%g-1. b - b
Table I also shows the 51Cr-labelled red blood cell esti- 12
mate of vascular volume for several normal tissues as well as
the tumours. By far the highest volume was in the kidney
(8.1%). Values for the tumours were slightly higher than o 10'
those for muscle and skin. The value for Hoechst 33342 c
perfusion volume of the SaFA tumour is included for
comparison. Hoechst estimates of the perfusion volume of o 8'
the tumours were always higher than those obtained by
51Cr-rbc measurement. 6
C 6(
Effect of MISO on vascular parameters of the SaFA c
and CaNT tumours
Figure 1 shows the vascular responses of the SaFA tumour 4 x assessed at a single time (2h) after a range of single doses of
MISO, measured by three different techniques. Both 2
Hoechst 33342 (Figure la) and 86RbCl extraction (Figure lb)
estimates showed a dose-dependent decrease to about 40%
of control values, which plateaued at 750mgkg 1 MISO
(P-A0 0S at 750 innd 1 ()mlkr- 1A k1 .V aL i JV ailu 1 VVV 111r6 )6
.
The estimates of vascular volume based upon 51Cr-
labelled red blood cells (Figure lc) showed a slight non-
ei;i1n1ir,aInt Au-nncta iin vnatvuiar v'.Jimi.. -WitI ;iii-n-ne;i. r i A
in the case of the SaFA.
Figure 2 shows the results of similar estimations carried
out on the CaNT tumour at 2 h after MISO treatment. Once
again a significant decrease in relative blood flow measured
by 86RbCl extraction (Figure 2a) was seen at doses in C
excess of 500 mgkg1. Values reached a minimum of 60% of
control. A slightly greater decrease was seen in vascular o
volume in the CaNT (Figure 2b, P<0.05) than in the SaFA. c
Figure 3 shows how relative blood flow varied with time
after different doses of MISO in the SaFA and CaNT. The
SaFA demonstrated a prolonged reduction of flow at the
highest dose of MISO (Figure 3a); at 24h relative blood °
flow was only 50% of control. By 48 h there was a
>
noticeable reduction in flow at all doses. In contrast, the
CaNT tumour demonstrated complete recovery by 48 h
u)
Table I Estimates of vascular parameters
86Rb 51Cr-rbc Hoechst
extraction volume volume
Tissue (% g-1) (%) (%)
Kidney (WHT) 26.3 +2.6 8.1 +0.8 -
Skin (WHT) 1.3 +0.2 1.8 +0.2
Muscle (WHT) 2.8+0.4 0.9+0.1 -
Muscle (CBA) 2.8+0.2 1.3+0.3
SaFA (WHT) 1.8+0.1 2.0+0.1 5.7+0.7
CaNT (CBA) 1.1 +0.2 2.8+0.3
250 500 750 1000
MISO (mg kg-')
Figure 1 The effect of single doses of MISO on vascular
parameters of the SaFA tumour at 2h after treatment, as
assessed by (a) Hoechst33342 perfusion, (b) 86RbCl extraction
and (c) 5"Cr-red blood cell distribution. All values expressed as
percentage of control.
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(Figure 3b). Although flow was reduced at 24 h at the
highest dose of MISO this was not significantly different
from controls.
Effect of MISO on vascular parameters of normal tissues
Figure 4 shows how both 86RbCl extraction (Figure 4a) and
'1Cr-rbc volume (Figure 4b) varied with time after MISO at
1,000 mgkg- 1 in several normal tissues of WHT mice as well
as the SaFA tumour. The profound drop in flow in both
skin (P<0.02) and SaFA tumour (P<0.05) at 2 h after
MISO treatment is clearly seen in Figure 3a, while muscle
and kidney were essentially unaffected. At 24h after treat-
ment relative blood flow remained reduced in the tumour
compared to normal tissues which had either recovered to
control level (skin, kidney) or risen, above control level
(muscle). By 48 h flow in all tissues was slightly below
control levels.
Figure 4b shows, that apart from skin, effects of MISO on
vascular volume of normal tissues were less pronounced than
on relative blood flow. Once again kidney showed no
significant changes over a 48 h period. Nor did the tumour
or muscle show significant deviations from control values.
Skin demonstrated an early fall in vascular volume followed
by a large increase above control at 24 (P<0.05) and 48h
after treatment.
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Figure 2 Effect of single doses of MISO on (a) 86RbCl extrac-
tion and (b) bCr-red blood cell distribution in the CaNT tumour
at 2 h after treatment.
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Figure 3 Effect of a single dose of MISO at 1,000mgkg-' on
the SaFA and CaNT tumours with time after MISO treatment.
(a) 86RbCl extraction, SaFA; (b) 86RbCl extraction, CaNT.
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Figure 4 Effect of a single dose of MISO at 1,000mgkg-1 on
blood flow (a) and vascular volume (b) in the SaFA tumour and
three normal tissues at varying times after treatment. ( *-,
SaFA tumour; - , skin; -
, muscle; --V--, kidney.)
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Figure 5 Changes in blood flow in the SaFA tumour relative to
skin at different times after a single dose of MISO at
1,O00mgkg -.
Discussion
MISO is known to reduce core temperature, respiration rate
and heart rate in mice at doses in excess of 500 mgkg-1
(Conroy et al., 1980; Chin & Rauth, 1981; Gomer &
Johnson, 1979). There have been no reports concerning the
effects of MISO on blood flow perse, although it has been
suggested that the effects of MISO at high doses are
'vascular' in nature (Conroy et al., 1980; Murray et al.,
1987). In general physiological parameters such as respi-
ration rate and core temperature appear to return to near
normal by 6-8 h after administration of MISO at doses in
excess of 500mg kg- 1. We believe the highly significant
reduction in relative blood flow seen in two different
tumours at 2 h after injection of MISO reflects a peripheral
vasoconstriction due to the drop in body temperature: effects
were observed in skin and muscle, whilst kidney was unaffec-
ted. The proportionally greater drop in tumour perfusion
than in skin may then be due to the inability of the tumour
to respond in an active manner to the drop in blood flow or
pressure around it. High internal resistance to flow, coupled
with vessel collapse due to raised interstitial pressure (Falk,
1978) might contribute further to the reduction in tumour
blood flow. The small changes seen in 5"Cr-rbc vascular
volume also suggest however that a degree of vaso-
constriction is coupled with a drop in cardiac output, as the
drop in flow appears to be greater than might be anticipated
simply from the vascular volume changes.
At 24 h after MISO there appears to be a compensatory
increase in both flow and vascular volume in normal tissues,
in some cases above control values. This vasodilation has
been previously observed microscopically in the sub-
epithelium of the rabbit trachea at periods of 24 h or longer
after MISO treatment (Albertsson et al., 1985). In spite of
this increase flow remains reduced in the tumour. This
phenomenon might be explained by assuming that the
tumour behaves passively and blood flow, in analogy with
electrical current, follows the path of least resistance. Our
previous microscopic observations with a basement
membrane-staining antibody (Murray et al., 1987) suggested
that there was a real decrease in vascular volume 24 and 48 h
later, perhaps due to vessel collapse. This is partly supported
by the 51Cr-rbc results, which indicate a drop of around
20% in tumour vascular volume at 24 and 48 h after MISO
treatment. Once again, it is difficult to compare the tech-
niques directly; whereas we may assume that the antibody to
basement membrane stains blood vessels of all sizes (Barsky
et al., 1983), the distribution of 51Cr-labelled rbcs may be
skewed in favour of larger vessels, underestimating the
contribution of very fine capillaries in the tumour. Therefore,
the evidence suggests that there may be changes in the
tumour vasculature per se at later times, which contribute to
the persistent diminution of blood flow. These observations
are perhaps best summarized in Figure 5 which shows blood
flow in the SaFA tumour expressed relative to that in skin.
At 2h perfusion is reduced in both skin and tumour. The
flow ratio is lowest at 24h, by which time skin has already
recovered but tumour flow has not. By 48 h the tumour has
started to perfuse normally again and the ratio returns to
normal.
Another possible mechanism of vascular damage may be
through a direct action on endothelial cells. MISO is cyto-
toxic to hypoxic cells in vitro and in vivo (Hall & Roizin-
Towle, 1975; Stratford & Adams, 1977). High doses of
MISO alone can induce massive necrosis in certain mouse
tumours (Brown, 1977) and it has been suggested that a
toxic metabolite produced in the hypoxic regions of the
tumour may diffuse freely to other regions, producing cyto-
toxicity. Vessel damage and collapse might result, further
damage being precipitated by the generation of new hypoxic
regions and further toxic metabolites.
Vascular effects as we have described may have important
implications for the use of MISO as a chemo- and radio-
sensitizing agent. In terms of the potentiation of alkylating
agent cytotoxicity, which requires relatively high doses of
MISO, changes in pharmacokinetics arising from vascular
effects may be important. Indeed, Randhawa et al. (1985)
have examined the effects of MISO on melphalan pharma-
cokinetics and show a substantial increase in the total
exposure of tumour to melphalan as a result of simultaneous
MISO treatment (see TableII). We have previously hypothe-
sized that the 'trapping' of melphalan by MISO-induced
vascular collapse was partly responsible for the resulting
growth delay (Murray et al., 1987), and this hypothesis is
currently being tested using vaso-active drugs such as hydra-
lazine, which reduces blood flow in the SaFA tumour and
potentiates the effects of melphalan as assessed by regrowth
delay, but which by itself is not cytotoxic (Murray &
Randhawa, unpublished).
Clinical use of MISO both as a chemo- and radiosensitizer
is limited by associated neuropathy, and therefore much
smaller doses have been used in man than in the mouse.
However the half-life of MISO in man is approximately 6-8
times longer than in mouse, so it is difficult to equate
dosages. From the point of view of chemosensitization it is
not clear whether peak dose, or total exposure (dose x time)
is the critical determinant. Several studies in the mouse have
attempted to model the human situation by the chronic
administration of MISO in combination with cytotoxic
agents. The results were equivocal; in one case the sensitizer
enhancement ratio; that is the dose of cytotoxin required to
achieve a given level of effect in the absence of sensitizer,
divided by the dose required to give the same effect in the
presence of sensitizer, was maintained compared to single
dosing (Hirst et al., 1982) and in others there was a loss of
enhancement (McNally et al., 1983; Twentyman & Work-
man, 1983; Randhawa et al., 1985). The administration of the
drug combination in the form of a fractionated regime using
higher doses, with intervals of the order of 1 day or more
did however result in the maintenance of SER in several
systems (Hill & Siemann, 1984; McNally et al., 1983;
Randhawa, unpublished). Our results would suggest that
Table II Pharmacokinetics of melphalan in SaFA tumour
MISO dose Melphalan dose
(mgkg-1) (mgkg-1)
0
1000
10
10
Tumour AUG
for melphalan
(pggmin-1)
364+ 101
924+267
Growth delay
(days)
2.6+ 1.0
12.8+1.2
.uu 36 48
- - -
r-
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longer intervals between MISO doses allow recovery of the
vasculature between fractions, consequently maintaining the
SER. Conversely, during chronic dosing experiments, MISO
levels were never high enough to achieve the required
vascular effect and therefore no sensitization was observed.
Whether this hypothesis is correct or not, it is clear from
our findings that experiments on murine tumours carried out
with high doses of MISO must be interpreted cautiously. We
have recently carried out similar blood flow measurements
on these same tumour models after treatment with the
lipophilic radiosensitizer Ro-03-8799, which also potentiates
several alkylating agents and nitrosoureas (Sheldon &
Gibson, 1984). We found that at 2 h after doses of
1,000mgkg-1 there was a 40% reduction in blood flow in
the SaFA tumour but little or no change in the CaNT
(Murray & Randhawa, unpublished). Again this is probably
due to peripheral vasoconstriction associated with a drop in
core temperature. Tamulevicius et al. (1987) reported a drop
of as much as 6'C in core temperature in mice after
treatment with Ro-03-8799 at doses of 1,000mgkg-1. There-
fore this phenomenon of decreased tumour blood flow is not
peculiar to MISO and must be considered as a possible
component of any therapeutic effects seen with nitro-
imidazole sensitizers. Indeed these results have wider impli-
cations in terms of the specific control of blood flow in
tumours. The use of agents which can increase the half-life
of other cytotoxins in the tumour may provide a novel
adjunct to conventional forms of therapy.
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